Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3692758017 | Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3692760015 | Benzocaine 20 mg/g and salicylamide 50 mg/g cutaneous gel | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Product containing benzocaine (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has active ingredient | Benzocaine (substance) | false | Inferred relationship | Some | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Product containing benzocaine and salicylamide (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | Cutaneous AND/OR transdermal dosage form | false | Inferred relationship | Some | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has active ingredient | Salicylamide | false | Inferred relationship | Some | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | Gel | false | Inferred relationship | Some | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | Cutaneous gel | true | Inferred relationship | Some | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Product containing benzocaine in topical dosage form | false | Inferred relationship | Some | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator value | 1 (kwalificatiewaarde) | false | Inferred relationship | Some | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Count of base of active ingredient | 2 (kwalificatiewaarde) | false | Inferred relationship | Some | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator value | 1 (kwalificatiewaarde) | false | Inferred relationship | Some | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator unit | g | true | Inferred relationship | Some | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator unit | g | true | Inferred relationship | Some | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has precise active ingredient | Salicylamide | false | Inferred relationship | Some | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator value | 20 (kwalificatiewaarde) | false | Inferred relationship | Some | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has basis of strength substance (attribute) | Salicylamide | false | Inferred relationship | Some | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has basis of strength substance (attribute) | Benzocaine (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has precise active ingredient | Benzocaine (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator value | 50 (kwalificatiewaarde) | false | Inferred relationship | Some | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Benzocaine and salicylamide only product in cutaneous dose form | true | Inferred relationship | Some | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has basis of strength substance (attribute) | Salicylamide | true | Inferred relationship | Some | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has basis of strength substance (attribute) | Benzocaine (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has precise active ingredient | Benzocaine (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has precise active ingredient | Salicylamide | true | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR